A Split Won’t “Make Or Break” Pfizer, CEO Read Says

The big pharma’s chief executive assured investors there is no expiration date on optionality, suggesting the company could always reconsider splitting up the business even if decides against such action this year.

Pfizer Inc. CEO Ian Read wasn’t giving away any clues during the company’s second quarter sales and earnings call Aug. 2 on which way the big pharma is leaning on the issue of breaking up the business, but he did remind investors there is a possibility that it won’t happen – and that such a decision wouldn’t necessarily be a bad development for Pfizer.

“This is not a make or break decision for the company,” Read assured investors. “I don’t view there being a wrong answer here. The decision will be taken straight through...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Loss Of Exclusivity Product Launches To Fuel Aurobindo’s FY26 Europe Growth

29 May 2025

• By Vibha Ravi

Aurobindo is banking on launches of loss of exclusivity products and biosimilars to fuel sales in Europe as it awaits a US announcement on tariffs and predicts high single-digit growth overall during FY26 for now

GSK’s Bet On Spero’s Oral cUTI Antibiotic Poised To Pay Off With New Phase III Data

28 May 2025

• By Joseph Haas

Spero and partner GSK have Phase III non-inferiority data to support approval of tebipenem as the first oral antibiotic for complicated urinary tract infections.